A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG
PHASE1CompletedINTERVENTIONAL
Enrollment
16
Participants
Timeline
Start Date
May 31, 2003
Study Completion Date
January 31, 2005
Conditions
Tuberculosis
Interventions
BIOLOGICAL
MVA85A
Trial Locations (1)
OX3 7LJ
Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital, Oxford
All Listed Sponsors
lead
University of Oxford
OTHER
NCT00427830 - A Phase I Study of the Safety and Immunogenicity of a Recombinant MVA Vaccine Encoding a Secreted Antigen From M. Tuberculosis, Antigen 85A, Delivered Intradermally by a Needle Injection in Healthy Volunteers Who Have Previously Received BCG | Biotech Hunter | Biotech Hunter